Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00569231 · ClinicalTrials.gov registry record · Phase 1
Study With Candida Antigen for Treatment of Warts
A Phase 1 study, sponsored by University of Arkansas.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT00569231 is a Phase 1 study that has completed, run by University of Arkansas. The registered enrollment target is 18 participants.
The verdict
NCT00569231, a Phase 1 study, has completed, sponsored by University of Arkansas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to look at how people respond to the treatment of warts through use of the Candida antigen to get an immune response to rid the body of human papillomavirus (HPV). The immune system is the part of the body that fights infections like HPV which causes warts. This research study will examine the response of your wart when injected with a portion of a common yeast (candida) which is the study drug. Your immune system response will also be looked at by doing a test called an ELISPOT assay. This test is done on blood samples. The results of this test may help us to determine how the Candida antigen affects your wart.
Interventions
- DRUG Candida Antigen
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2007-02 |
| Est. Completion | 2010-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00569231
The ClinicalTrials.gov registry entry for NCT00569231 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Arkansas, which has 318 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Candida Antigen is the first listed.
NCT00569231 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00569231 about?
NCT00569231 is a clinical study titled "Study With Candida Antigen for Treatment of Warts". The purpose of this study is to look at how people respond to the treatment of warts through use of the Candida antigen to get an immune response to rid the body of human papillomavirus (HPV). The immune system is the part of the body that fights infections like HPV which causes warts. This research...
What is the current status of trial NCT00569231?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2007-02. Estimated completion is 2010-01.
What interventions are being tested in trial NCT00569231?
The interventions under investigation include: Candida Antigen (DRUG).
Who is sponsoring clinical trial NCT00569231?
This trial is sponsored by University of Arkansas, which has 318 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.